Ocata Therapeutics Inc fka OCAT

[rocky301]

rumit,

I guess the time frame is in line, it's a long ways out especially since we haven't started a trial yet ..below are some links on your article and some others may not have seen...thanks

here is the same article posted on I-hub from the past
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38177078&txt2find=Revazova

Intellectual Property Relating to Collaboration with International Stem Cell Corporation
http://www.embryome.com/iprop.htm
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=35357330

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=33619008

ISCO's human parthenogenetic stem cells have the potential to treat human disease yet possess key medical and ethical advantages over other kinds of stem cell products. They can be matched to common immune types and thus reduce the chance of transplant rejection among large segments of the population. Because they are created from unfertilized human eggs, they do not require the destruction of human embryos.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=34779607

5. Patent Licenses
"On December 31, 2003, Lifeline entered into an Option to License Intellectual Property agreement with Advanced Cell Technology, Inc. (“ACT”) for patent rights and paid ACT $340,000 in option and license fees. On February 13, 2004, Lifeline and ACT amended the Option agreement and Lifeline paid ACT additional option fees of $22,500 for fees related to registering ACT’s patents in selected international countries.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=35261637

One of ACTC's licensee's
OCEANSIDE, Calif., Jan 13, 2009 (BUSINESS WIRE) -- International Stem Cell Corporation (OTCBB: ISCO) has created layered human tissue from its unique parthenogenetic stem cells and transplanted this tissue into animals in pre-clinical trials to establish a potential new treatment for human retinal diseases, such as macular degeneration or retinitis pigmentosa.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=36975910

In addition, we have obtained the exclusive worldwide licenses to a portfolio of patents and patent applications from Advanced Cell Technology.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=38134844